Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.

Bouérat L, Fensholdt J, Liang X, Havez S, Nielsen SF, Hansen JR, Bolvig S, Andersson C

LEO Pharma A/S, Industriparken, DK-2750 Ballerup, Denmark. laetitia.bouerat@leo-pharma.com

The known KDR inhibitor SU5416 and several analogues of the indolin-2-one family were surprisingly found to be highly efficacious in the EAE model, an established model for multiple sclerosis. The high in vivo effect could be correlated to in vitro inhibition of the pro-inflammatory cytokine IL-2. Activity following po administration was obtained with several analogues and via the use of prodrugs.

Published 18 August 2005 in J Med Chem, 48(17): 5412-4.
Full-text of this article is available online (may require subscription).

© 2004-2008 Multiple Sclerosis Research Today. All Rights Reserved.